November 23, 2016 - By Richard Conner
Atara Biotherapeutics Inc Chief Operating Officer Gad Soffer on the November 21, 2016 unloaded a total of 1,480 shares of the public company worth $27,247 US Dollars. This is exactly based on the average stock price value of $18.4 US Dollars. Gad is trying to silently decrease his company’s share, same as he did in the last 30 days. He unloaded another 16,718 shares worth $334,421 USD. Mr. Gad now holds 230,812 shares, accounting for 0.81% of the Company’s market cap. This sale was completed on November 21, 2016. A legal report filed with the D.C. based-SEC and available for review here, discloses more information for the sale.
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. $80 is the highest target while $8 is the lowest. The $36.50 average target is 99.45% above today’s ($18.3) stock price. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Sell” rating given on Friday, August 19 by Citigroup. The rating was initiated by Canaccord Genuity on Wednesday, September 9 with “Buy”. The rating was downgraded by Citigroup to “Sell” on Tuesday, December 15. The rating was initiated by William Blair on Friday, October 9 with “Outperform”. The stock has “Mkt Perform” rating given by JMP Securities on Friday, September 25. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, November 18. The rating was downgraded by Goldman Sachs to “Sell” on Thursday, September 15. The rating was maintained by Citigroup on Monday, August 22 with “Sell”. The firm earned “Buy” rating on Monday, October 24 by Jefferies. JMP Securities maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) on Wednesday, March 9 with “Market Outperform” rating.
Insitutional Activity: The institutional sentiment decreased to 1.48 in Q2 2016. Its down 1.88, from 3.36 in 2016Q1. The ratio dropped, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Teachers Retirement Systems Of The State Of Kentucky holds 126,400 shares or 0.04% of its portfolio. The California-based Wells Fargo Mn has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). 12 West Capital Management L P holds 1.45% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 398,700 shares. The Maryland-based Price T Rowe Assoc Inc Md has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Slate Path Limited Partnership has invested 0.74% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). State Street reported 355,001 shares or 0% of all its holdings. Pnc, a Pennsylvania-based fund reported 6,563 shares. Redmile Gp Limited Com, a California-based fund reported 2.41M shares. Teachers Advsrs has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Northern Tru Corporation reported 240,735 shares or 0% of all its holdings. Deutsche State Bank Ag holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 9,779 shares. Bridger Mngmt Ltd Liability Co reported 1.02 million shares or 1.48% of all its holdings. The New York-based Goldman Sachs Group Inc Inc Inc has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Ubs Asset Americas last reported 1.15M shares in the company. Citigroup Incorporated last reported 5,996 shares in the company.
Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 16 selling transactions for $2.21 million net activity. Soffer Gad also sold $334,421 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, November 14. $32,000 worth of shares were sold by Haqq Christopher on Tuesday, November 15. Ciechanover Isaac E. also sold $246,372 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Tuesday, June 7. $99,175 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares were sold by MCGRATH JOHN. 2,995 shares were sold by Clark Mitchall G., worth $58,492. $22,910 worth of shares were sold by Gallagher Carol Giltner on Tuesday, November 15.
The stock decreased 1.61% or $0.3 during the last trading session, hitting $18.3. About 178,415 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 10.06% since April 20, 2016 and is downtrending. It has underperformed by 14.61% the S&P500.
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $544.24 million. The Company’s segment is the business of developing and commercializing therapeutics. It currently has negative earnings. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Fool.com which released: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Also Marketwatch.com published the news titled: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.